RESUMEN
PURPOSE: Coffee drinking has been linked to many positive health effects, including reduced risk of some cancers. The present study aimed to provide an overview of the collective evidence on the association between coffee consumption and risk of colorectal cancer (CRC) through an umbrella review of the published systematic reviews. METHODS: This PRISMA-compliant systematic review of systematic reviews assessed the association between coffee drinking and the risk of CRC. An umbrella review approach was followed in a qualitative narrative manner. The quality of included reviews was assessed by the AMSTAR 2 checklist. The main outcome was the association between coffee drinking and CRC and colon and rectal cancer separately. RESULTS: Fourteen systematic reviews were included in this umbrella review. Coffee drinking was associated with a significant reduction in the risk of CRC according to five reviews (11-24%), colon cancer according to two reviews (9-21%), and rectal cancer according to one review (25%). One review reported a significant risk reduction of CRC by 7% with drinking six or more cups of coffee per day and another review reported a significant risk reduction of 8% with five cups per day reaching 12% with six cups per day. Decaffeinated coffee was associated with a significant risk reduction according to three reviews. CONCLUSION: The evidence supporting caffeinated coffee as associated with a reduced risk of CRC is inconsistent. Dose-dependent relation analysis suggests that the protective effect of coffee drinking against CRC is evident with the consumption of five or more cups per day.
Asunto(s)
Neoplasias del Colon , Neoplasias del Recto , Humanos , Cafeína , Café , Factores de Riesgo , Revisiones Sistemáticas como AsuntoRESUMEN
BACKGROUND: Gracilis muscle interposition (GMI) has been associated with favorable outcomes in treating complex perianal fistulas. Outcomes of GMI may vary according to the fistula etiology, particularly between rectovaginal fistulas in women and rectourethral fistulas (RUF) in men. The aim of this study was to assess the outcome of GMI to treat RUF acquired after prostate cancer treatment. METHODS: This retrospective cohort study included male patients treated with GMI for RUF acquired after prostate cancer treatment between January 2000 and December 2018 in the Department of Colorectal Surgery, Cleveland Clinic Florida. The primary outcome was the success of GMI, defined as complete healing of RUF without recurrence. Secondary outcomes were length of hospital stay and postoperative complications. RESULTS: This study included 53 male patients with a median age of 68 (range, 46-85) years. Patients developed RUF after treatment of prostate cancer with radiation (52.8%), surgery (34%), or transurethral resection of the prostate (TURP) (13.2%). Median hospital stay was 5 (IQR, 4-7) days. Twenty (37.7%) patients experienced 25 complications, the most common being wound infection and dehiscence. Primary healing after GMI was achieved in 28 (52.8%) patients. Fifteen additional patients experienced successful healing of RUF after additional procedures, for a total success rate of 81.1%. Median time to complete healing was 8 (range, 4-56) weeks. The only significant factor associated with outcome of GMI was wound dehiscence (p = 0.008). CONCLUSIONS: Although the initial success rate of GMI was approximately 53%, it increased to 81% after additional procedures. Complications after GMI were mostly minor, with wound complications being the most common. Perianal wound dehiscence was significantly associated with failure of healing of RUF after GMI.
Asunto(s)
Músculo Grácil , Neoplasias de la Próstata , Fístula Rectal , Resección Transuretral de la Próstata , Enfermedades Uretrales , Fístula Urinaria , Humanos , Masculino , Femenino , Persona de Mediana Edad , Anciano , Anciano de 80 o más Años , Músculo Grácil/trasplante , Resección Transuretral de la Próstata/efectos adversos , Estudios Retrospectivos , Fístula Rectal/etiología , Fístula Rectal/cirugía , Fístula Urinaria/etiología , Fístula Urinaria/cirugía , Enfermedades Uretrales/etiología , Enfermedades Uretrales/cirugía , Complicaciones Posoperatorias/etiología , Complicaciones Posoperatorias/cirugía , Neoplasias de la Próstata/cirugía , Resultado del TratamientoRESUMEN
BACKGROUND: The aim of this study was to assess the effect of preoperative biologic therapy on the surgical outcome of Crohn's disease (CD) patients undergoing repeat ileocolic resection. METHODS: This was a retrospective analysis of all CD patients who underwent repeat ileocolic resection at Cleveland Clinic Florida between January 2011 and April 2021. Patients were divided into two groups: treatment biologic therapy prior to surgery and controls. RESULTS: Sixty-five patients (31males, median age 54 [range 23-82] years) were included in the study. Twenty nine (44.6%) were treated with biologic therapy prior to repeat ileocolic resection. No demographic differences were found between the biologic therapy and control groups. In addition, no differences were found in mean time from index ileocolic resection (p = 0.9), indication for surgery (p = 0.11), and preoperative albumin (p = 0.69). The majority of patients (57; 87.7%) were operated on laparoscopically, and mean overall operation time was 225 (SD 49.27) min. Overall, the postoperative complication rate was 43.1% (28 patients) and median length of stay was 5 (range 2-21) days. Postoperative complications were more common in the control group, compared to the biologic therapy group (55.6 vs 27.5%; p = 0.04). Conversion rate (35.7 vs 20.7%; p = 0.24), operation time (223 vs 219 min; p = 0.75), length of stay (5.2 vs 5.9 days; p = 0.4), and readmission (16.6 vs 11.1%; p = 0.72) were similar between the two groups. Multivariate analysis of risk factors for postoperative complications showed that biologic treatment was correlated with a lower risk (HR -0.28, CI 95% -0.5596 to -0.01898, p = 0.03). CONCLUSIONS: Patients treated with biologic therapy for CD who underwent repeat ileocolic resection had fewer postoperative complications.